LinusBio raises $16M for novel platform to aid diagnosis, treatment of ALS, autism
Click Here to Manage Email Alerts
LinusBio announced it has raised over $16 million in Series A funding to deliver technology that combines genomics, the environment and biological response to help diagnose and monitor the progression of disorders such as ALS and autism.
According to a release from LinusBio, the novel platform also aims to improve clinical trials by providing data comparable to more than 500 liquid biopsies or blood samples, from just a single strand of hair.
The company’s initial focus is on neurological disorders, and it aims to use the platform to identify novel compounds for health conditions for which genomic biomarkers have previously had limited success.
“Our mission is simple: to deliver better outcomes for people and families affected by complex health conditions,” Manish Arora, PhD, CEO and co-founder of LinusBio, stated in the release. “We’re proud to launch the LinusBio platform to meet the tremendous need for better, faster and comprehensive diagnostics and treatments for a range of conditions and diseases.”
The company’s program pipeline also includes advanced biomarkers for oncology, gastroenterology and mental health disorders, according to the release.